FOLH1 and nonpapillary renal cell carcinoma: PET/CT with PSMA-targeting radiopharmaceuticals has the potential to assess the treatment response in ccRCC patients receiving tyrosine–kinase inhibitor or anti-angiogenic treatments [19,20].